ChromaDex (CDXC) Projected to Post Quarterly Earnings on Wednesday

ChromaDex (NASDAQ:CDXC) is expected to post its quarterly earnings results before the market opens on Wednesday, March 5th. Analysts expect ChromaDex to post earnings of $0.02 per share and revenue of $26.51 million for the quarter.

ChromaDex Stock Performance

Shares of NASDAQ:CDXC opened at $5.44 on Wednesday. The firm has a fifty day moving average of $5.62 and a 200 day moving average of $5.00. ChromaDex has a 52-week low of $1.51 and a 52-week high of $7.97. The firm has a market capitalization of $415.52 million, a PE ratio of 544.54 and a beta of 2.21.

Insider Activity

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the sale, the director now directly owns 244,179 shares in the company, valued at $1,511,468.01. This represents a 13.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 9.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. StockNews.com upgraded ChromaDex from a “buy” rating to a “strong-buy” rating in a research report on Monday. HC Wainwright increased their price target on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, November 4th. Finally, Roth Mkm boosted their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.